Study Progression on Non-small Cell Lung Cancer with EGFR Mutation 
Treated by Immune Checkpoint Inhibitors

Study Progression on Non-small Cell Lung Cancer with EGFR Mutation 
Treated by Immune Checkpoint Inhibitors

In recent years, epidermal growth factor receptor tyrosine kinase inhibitors have been recommended by many guidelines as first-line drugs for advanced non-small cell lung cancer (NSCLC) with EGFR gene mutations and no resistance. However, with the prolongation of medication time, most appear acquire...

Full description

Bibliographic Details
Main Authors: Rilan BAI, Naifei CHEN, Jiuwei CUI
Format: Article
Language:zho
Published: Chinese Anti-Cancer Association; Chinese Antituberculosis Association 2018-08-01
Series:Chinese Journal of Lung Cancer
Subjects:
Immune checkpoint inhibitors
Lung neoplasms
EGFR mutation
PD-L1
Online Access:http://dx.doi.org/10.3779/j.issn.1009-3419.2018.08.11

Internet

http://dx.doi.org/10.3779/j.issn.1009-3419.2018.08.11

Similar Items